Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Central Nervous System Lymphoma (SCNSL)”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Early research (Phase 1)Looking for participantsNCT05131022
What this trial is testing

NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Diffuse Large B Cell Lymphoma (DLBCL)+6 more
Nurix Therapeutics, Inc. 572
Testing effectiveness (Phase 2)UnknownNCT04438044
What this trial is testing

Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

Who this might be right for
PCNSLSecondary Central Nervous System Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. 61
Early research (Phase 1)Study completedNCT03703167
What this trial is testing

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Who this might be right for
Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center 25
Testing effectiveness (Phase 2)Looking for participantsNCT05698147
What this trial is testing

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Who this might be right for
Central Nervous System Lymphoma
Tong Chen, MD 30
Testing effectiveness (Phase 2)UnknownNCT05398224
What this trial is testing

R-MTX-zanbrutinib in Secondary CNS Lymphoma

Who this might be right for
Secondary Central Nervous System Lymphoma
Peking University 45
Early research (Phase 1)Ended earlyNCT05242146
What this trial is testing

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

Who this might be right for
CNS Lymphoma
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 12
Early research (Phase 1)Active Not RecruitingNCT05211336
What this trial is testing

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Who this might be right for
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)UnknownNCT04457869
What this trial is testing

F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
Shandong New Time Pharmaceutical Co., LTD 43
Early research (Phase 1)Looking for participantsNCT07082868
What this trial is testing

Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Who this might be right for
Primary Central Nervous System Lymphoma (PCNSL)Primary Central Nervous System LymphomaRelapsed Primary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center 26
Testing effectiveness (Phase 2)Study completedNCT02301364
What this trial is testing

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
LymphomaPrimary Central Nervous System LymphomaRecurrent/Refractory Secondary Central Nervous System Lymphoma
Memorial Sloan Kettering Cancer Center 4
Early research (Phase 1)Temporarily pausedNCT07555561
What this trial is testing

Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma

Who this might be right for
Relapsed/Refractory Central Nervous System LymphomaRelapsed/Refractory Primary Central Nervous System LymphomaRelapsed/Refractory Secondary Central Nervous System Lymphoma
Beijing Boren Hospital 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05485753
What this trial is testing

GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd. 7
Testing effectiveness (Phase 2)Study completedNCT02315326
What this trial is testing

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center 93
Testing effectiveness (Phase 2)Looking for participantsNCT07410520
What this trial is testing

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

Who this might be right for
Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University 50
Testing effectiveness (Phase 2)Ended earlyNCT06625359
What this trial is testing

High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma

Who this might be right for
Central Nervous System Lymphoma
Seoul National University Hospital 17
Testing effectiveness (Phase 2)Looking for participantsNCT04792489
What this trial is testing

DALY II USA/ MB-CART2019.1 for DLBCL

Who this might be right for
Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+5 more
Miltenyi Biomedicine GmbH 248